MedPath

SARDELLA GENNARO

🇮🇹Italy
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:0
Completed:3

Trial Phases

1 Phases

Phase 3:6

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3
6 (100.0%)

Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome

Phase 3
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2013-01-29
Last Posted Date
2013-01-29
Lead Sponsor
Gennaro Sardella
Target Recruit Count
68
Registration Number
NCT01778842
Locations
🇮🇹

Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus

Phase 3
Completed
Conditions
ST-Elevation Myocardial Infarction
Interventions
First Posted Date
2012-02-10
Last Posted Date
2017-06-28
Lead Sponsor
Gennaro Sardella
Target Recruit Count
50
Registration Number
NCT01531114
Locations
🇮🇹

Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

Impact of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction (NSTEMI) Patients: One Stage Versus Multistaged Percutaneous Coronary Intervention (PCI)

Phase 3
Conditions
Non ST Segment Elevation MI and Unstable Angina
First Posted Date
2011-11-24
Last Posted Date
2011-11-24
Lead Sponsor
Gennaro Sardella
Target Recruit Count
247
Registration Number
NCT01478984
Locations
🇮🇹

Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial

Phase 3
Completed
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2011-11-06
Last Posted Date
2012-03-27
Lead Sponsor
Gennaro Sardella
Target Recruit Count
30
Registration Number
NCT01465828
Locations
🇮🇹

Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading

Phase 3
Completed
Conditions
Assess the Periprocedural Myocardial Necrosis
Interventions
First Posted Date
2010-10-26
Last Posted Date
2013-01-04
Lead Sponsor
Gennaro Sardella
Target Recruit Count
310
Registration Number
NCT01228227
Locations
🇮🇹

Policlinico Umberto I, Roma, Italy

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.